The Claim
Pharmacological activation of HSP72 using BGP-15 in diabetic rats increases mitochondrial area in skeletal muscle and improves insulin sensitivity to a degree comparable to metformin or rosiglitazone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In diabetic rats, a drug called BGP-15 that activates HSP72 increases the size of mitochondria in skeletal muscle and improves insulin sensitivity to the same extent as the drugs metformin or rosiglitazone.
See the scientific wording
Pharmacological activation of HSP72 using BGP-15 in diabetic rats increases mitochondrial area in skeletal muscle and improves insulin sensitivity to a degree comparable to metformin or rosiglitazone, suggesting HSP72-inducing compounds may have therapeutic potential for type 2 diabetes.
When HSP72 levels rise in muscle, it triggers more mitochondria to form and boosts the muscle's ability to burn fat. This reduces fat buildup inside muscle cells, which allows insulin to work better and lowers blood sugar.
What the research says
1 studyA drug called BGP-15, which boosts a protective protein in muscle, made diabetic rats produce more energy-producing mitochondria and better control their blood sugar—just as well as two common diabetes medicines.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.